Loading...
Cohance Lifesciences Limited — Tetracycline Export Profile: Buyers & Destinations
Loading...
Indian Pharmaceutical Exporter · #4 for Tetracycline · $1.5M export value · DGFT Verified
Cohance Lifesciences Limited is the #4 Indian exporter of Tetracycline with $1.5M in export value and 36 verified shipments. Cohance Lifesciences Limited holds a 8.6% market share in Tetracycline exports across 1 countries. The company exports 4 pharmaceutical products worth $13.6M across 4 therapeutic categories.
| Country | Value | Shipments | Share |
|---|---|---|---|
| UNITED STATES | $1.9M | 92 | 16.8% |
| TANZANIA | $1.9M | 37 | 16.3% |
| CONGO DR | $1.5M | 61 | 13.3% |
| ETHIOPIA | $1.5M | 67 | 13.3% |
| UZBEKISTAN | $616.7K | 44 | 5.4% |
| ANGOLA | $577.8K | 59 | 5.1% |
| MOZAMBIQUE | $539.8K | 94 | 4.8% |
| CONGO | $523.6K | 18 | 4.6% |
| KENYA | $438.2K | 43 | 3.9% |
| NIGERIA | $404.7K | 18 | 3.6% |
India exports Tetracycline to 128 countries. The top destination is UNITED STATES (16.8%), followed by TANZANIA and CONGO DR.
| Buyer | Country | Value | Orders |
|---|---|---|---|
| STE PRINCE PHARMA SARL | CONGO DR | $1.8M | 72 |
| CARDINAL HEALTH | UNITED STATES | $1.5M | 39 |
| HEKO PHARMACY LTD | TANZANIA | $400.0K | 8 |
| PRINCE FARMA LDA, | ANGOLA | $251.9K | 7 |
| TROGE MEDICAL GMBH | GERMANY | $250.0K | 5 |
| IMRES B.V. |
India exported $9.7M worth of Tetracycline through 2,829 shipments from 263 suppliers to 128 countries, serving 660 buyers globally. Cohance Lifesciences Limited contributes $1.5M to this total, accounting for 8.6% of India's Tetracycline exports.
Cohance Lifesciences Limited's average Tetracycline shipment value is $40.5K per consignment, based on 36 shipments totaling $1.5M.
Cohance Lifesciences Limited ranks #4 among 263 Indian Tetracycline exporters with a 8.6% market share. The top 3 exporters are GALENTIC PHARMA INDIA PVT LTD ($2.3M), PRASHI PHARMA PRIVATE LIMITED ($1.5M), COHANCE LIFESCIENCES LIMITED ($1.5M). Cohance Lifesciences Limited processed 36 shipments to 1 destination countries.
What Cohance Lifesciences Limited must comply with to export Tetracycline to its top destination countries
Approval Process
ANDA (Abbreviated New Drug Application) for generics. Indian manufacturing site must pass FDA pre-approval inspection. Drug Master File (DMF) required for APIs.
Timeline: 10–18 months for ANDA approval
GMP & Export Requirements
FDA cGMP compliance (21 CFR 210/211); facility inspection by FDA
Drug Listing with FDA; Export Certificate from CDSCO India; Import Alert screening via FDA PREDICT system
Note: Subject to FDA Import Alerts. Open Form 483 observations can block all exports from a facility.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
Exporters ranked immediately above and below #4 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 2 | GALENTIC PHARMA INDIA PVT LTD | $2.3M | 85 | 13 | $27.2K |
| 3 | PRASHI PHARMA PRIVATE LIMITED | $1.5M | 63 | 4 | $23.4K |
| 4 | COHANCE LIFESCIENCES LIMITED ★ | $1.5M | 36 | 1 | $40.5K |
| 1 | LINCOLN PHARMACEUTICALS LTD | $700.0K |
| Port | Shipments | % Share |
|---|---|---|
| DELHI AIR CARGO ACC (INDEL4) | 438 | 15.5% |
| SAHAR AIR CARGO ACC (INBOM4) | 393 | 13.9% |
| SAHAR AIR | 355 | 12.5% |
| DELHI AIR | 253 | 8.9% |
| NHAVA SHEVA SEA (INNSA1) | 224 | 7.9% |
| JNPT | 130 | 4.6% |
| Bombay Air | 121 | 4.3% |
| JNPT/ NHAVA SHEVA SEA | 114 | 4.0% |
The current geopolitical landscape presents both challenges and opportunities for Indian pharmaceutical exporters like Cohance Lifesciences. The Israel-Iran tensions have led to disruptions in Red Sea shipping routes, increasing transit times and shipping costs. This situation necessitates strategic adjustments in logistics and supply chain management to maintain timely deliveries and cost efficiency.
Conversely, the U.S.-China trade tensions have opened avenues for Indian exporters to capture market share previously dominated by Chinese manufacturers. Cohance's established presence and compliance with international standards position it favorably to meet the increased demand from U.S. importers seeking reliable alternatives.
The recent India-European Union Free Trade Agreement (FTA), concluded on January 27, 2026, eliminates tariffs on Indian pharmaceutical exports to the EU, including duties of up to 11% on pharmaceuticals. This development enhances Cohance's competitiveness in the European market, potentially boosting export volumes and revenues. (en.wikipedia.org)
Compliance with international regulatory standards is paramount for pharmaceutical exporters. The USFDA's issuance of a warning letter to Cohance's Hyderabad facility highlights the critical importance of adhering to Good Manufacturing Practices (GMP). While the immediate financial impact may be minimal due to the facility's limited contribution to U.S. revenues, the long-term implications on reputation and market access are significant. Proactive remediation and transparent communication with regulatory bodies are essential to restore and maintain compliance.
Additionally, the European Union's Falsified Medicines Directive (FMD) imposes stringent requirements on pharmaceutical imports. Cohance must ensure robust serialization and traceability measures to comply with these regulations, thereby safeguarding its access to the lucrative EU market.
Cohance Lifesciences Limited exports 4 products worth $13.6M. Beyond Tetracycline, top products include Isosorbide, Itraconazole, Spironolactone. View the complete Cohance Lifesciences Limited profile for full portfolio analysis.
Latest developments and market context
Detailed market intelligence for Tetracycline — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Cohance Lifesciences Limited's Tetracycline exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Cohance Lifesciences Limited
Full Company Profile →
4 products · $13.6M total trade · 4 categories
| NETHERLANDS |
| $219.6K |
| 12 |
| ETHIOPIAN PHARMACEUTICALS SUPPLY | ETHIOPIA | $150.0K | 3 |
| UNICEF SUPPLY DIVISION | DENMARK | $100.0K | 2 |
| NEW CESAMEX S | CONGO | $100.0K | 2 |
| ETHIOPIAN PHARMACEUTICALS | ETHIOPIA | $100.0K | 2 |
India's Tetracycline is purchased by 660 buyers worldwide. The top buyer is STE PRINCE PHARMA SARL (CONGO DR), followed by CARDINAL HEALTH and HEKO PHARMACY LTD.
| 14 |
| 2 |
| $50.0K |
| 5 | VIDACARE MEDICA PRIVATE LIMITED | $558.4K | 18 | 3 | $31.0K |
Cohance Lifesciences Limited ranks #4 among 263 Indian Tetracycline exporters. Average shipment value of $40.5K compared to the market average of $36.8K. The closest competitors by value are GALENTIC PHARMA INDIA PVT LTD and PRASHI PHARMA PRIVATE LIMITED.
Verify manufacturer licensing and export certifications with the official agencies above.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 128+ countries, 660+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Access shipment-level records, pricing trends, and buyer contacts for Cohance Lifesciences Limited.
Request DemoView Pricing →Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Tetracycline. For current shipment-level data, contact TransData Nexus.